TG Therapeutics | TGTX - Selling And Administration Expenses


TG Therapeutics reported $63.37M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Alaunos Therapeutics USD 585K 260K Sep/2025
Amgen USD 1.94B 237M Dec/2025
Ardelyx USD 83.61M 378K Sep/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
Bayer EUR 3.4B 140M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
Corcept Therapeutics USD 106.97M 3.12M Sep/2025
Curis USD 4.79M 100K Jun/2024
Gilead Sciences USD 1.78B 425M Dec/2025
Infinity Pharmaceuticals USD 3.75M 2.19M Jun/2023
J&J USD 6.75B 831M Dec/2025
Karyopharm Therapeutics USD 27.19M 442K Dec/2024
Novartis USD 3.31B 134M Sep/2025
Novavax USD 66.95M 34.05M Sep/2024
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
TG Therapeutics USD 63.37M 51.33M Sep/2025
Verastem USD 12.28M 2.06M Sep/2024
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025